The estimated Net Worth of Fred T Hadeed is at least $1.78 Миллион dollars as of 17 August 2006. Fred Hadeed owns over 3,819 units of United Therapeutics Corp stock worth over $1,668,290 and over the last 20 years Fred sold UTHR stock worth over $113,704.
Fred has made over 41 trades of the United Therapeutics Corp stock since 2004, according to the Form 4 filled with the SEC. Most recently Fred exercised 3,819 units of UTHR stock worth $87,646 on 17 August 2006.
The largest trade Fred's ever made was exercising 3,819 units of United Therapeutics Corp stock on 17 August 2006 worth over $87,646. On average, Fred trades about 2,996 units every 14 days since 2004. As of 17 August 2006 Fred still owns at least 4,819 units of United Therapeutics Corp stock.
You can see the complete history of Fred Hadeed stock trades at the bottom of the page.
Fred's mailing address filed with the SEC is , , , , .
Over the last 20 years, insiders at United Therapeutics Corp have traded over $68,910,395 worth of United Therapeutics Corp stock and bought 229,703 units worth $13,655,671 . The most active insiders traders include Martine A Rothblatt, David Zaccardelli и Roger Jeffs. On average, United Therapeutics Corp executives and independent directors trade stock every 3 days with the average trade being worth of $2,310,818. The most recent stock trade was executed by James Edgemond on 9 September 2024, trading 8,332 units of UTHR stock currently worth $991,341.
united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians
United Therapeutics Corp executives and other stock owners filed with the SEC include: